Trimtech Therapeutics, a biotech company creating novel, small molecule therapeutics that selectively degrade protein aggregates, to combat neurodegenerative diseases, has announced the formation of its scientific advisory board.
Globally recognised leaders within the protein degradation and technology development fields, Professor Alessio Ciulli FRS, FRSE, FRSC, and Dr Adam Gilbert, have been appointed as chair and member of the scientific advisory board, respectively. The newly formed scientific advisory board will support development of Trimtech’s targeted protein degradation (TPD) Trimtac™ and Trimglue™ platform, and progression of its small molecule therapeutic pipeline for neurodegenerative and inflammatory disorders.
Professor Alessio Ciulli is chair of chemical and structural biology and founder and director of the world-leading Centre for Targeted Protein Degradation (CeTPD) at the University of Dundee.
Dr Adam Gilbert has over 30 years of experience in pharma, including his previous position as executive director and external accelerator lead, and executive director of design and synthesis sciences, at Pfizer. He is currently a scientific advisor to Axiom Therapeutics, PhoreMost and Gero.AI.
